High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: a LOC network study - Scorecard - MDSpire
Advertisement
High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: a LOC network study
Clinical Scorecard: Administration of High-Dose Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplantation for Isolated Vitreoretinal Lymphoma: Insights from a LOC Network Analysis
At a Glance
Category
Detail
Condition
Isolated vitreoretinal lymphoma (VRL), primarily diffuse large B-cell type
Key Mechanisms
High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (HCT-ASCT) as consolidation treatment
Target Population
Immunocompetent adults (>18 years) with isolated VRL without cerebral or CSF involvement
Care Setting
Multidisciplinary care involving ophthalmologists, hematologists, and neurologists in specialized centers
Key Highlights
Isolated VRL is an indolent but high-risk lymphoma with 40-90% risk of CNS progression within 30 months.
HCT-ASCT is used as consolidation after induction therapy and is included in French treatment recommendations for primary VRL.
In a retrospective cohort of 38 patients, 87% achieved complete response after HCT-ASCT with a median age of 61 years.
Guideline-Based Recommendations
Diagnosis
Exclude cerebral and cerebrospinal fluid involvement by cerebral MRI and lumbar puncture before HCT-ASCT.
Confirm diagnosis by pathological or cytological analysis of vitreous samples.
Measure IL-10 levels in aqueous humour as a biomarker, with >30 pg/ml considered elevated.
Management
Use high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation as consolidation treatment after induction therapy.
Induction therapy regimens often include high-dose methotrexate-based protocols analogous to primary CNS lymphoma treatment.
Multidisciplinary approach involving ophthalmology, hematology, and neurology is essential.
Monitoring & Follow-up
Assess response post-HCT-ASCT using IPCG criteria: complete response, partial response, stable disease, or progressive disease.
Monitor IL-6 and IL-10 levels in aqueous humour when available to evaluate disease activity.
Follow progression-free survival, brain-free survival, and overall survival using Kaplan–Meier analysis.
Risks
Potential toxicity related to high-dose chemotherapy and stem cell transplantation assessed by Common Terminology Criteria for Adverse Events v4.
Risk of CNS progression despite treatment, necessitating close neurological monitoring.
Patient & Prescribing Data
38 immunocompetent adult patients with isolated VRL treated between 2008 and 2019 in France.
Majority received thiotepa-based conditioning; 87% achieved complete response post-HCT-ASCT; treatment applied mostly in second-line or later settings.
Clinical Best Practices
Confirm isolated VRL diagnosis with imaging and CSF studies to exclude CNS involvement prior to HCT-ASCT.
Employ high-dose methotrexate-based induction therapy followed by HCT-ASCT consolidation for eligible patients.
Use multidisciplinary teams for diagnosis, treatment planning, and follow-up.
Monitor ocular disease activity clinically and via IL-10 aqueous humour levels.
Assess treatment response using standardized IPCG criteria.
Be vigilant for treatment-related toxicities and manage accordingly.
